10 Points On Dostarlimab, The Drug That 'Cured' Cancer During Trials

NDTV - 08 Jun 2022
The clinical trial comprised a group of 18 patients. All of them were battling rectal cancer at the Memorial Sloan Kettering Cancer Center in Manhattan, US. In ...

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell ...

Nature.com - 11 Nov 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell ... ...

FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer

Pharmacy Times - 25 Apr 2024
FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer ...

Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer

ScienceDirect.com - 18 Oct 2023
Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer ...

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

Cancer Network - 24 Apr 2024
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers ...

NICE Recommends Dostarlimab Plus Chemo in MSI-High/dMMR Endometrial Cancer

OncLive - 05 Mar 2024
NICE Recommends Dostarlimab Plus Chemo in MSI-High/dMMR Endometrial Cancer ...

Dostarlimab given NICE go-ahead in first-line combination treatment for endometrial cancer

Hospital Healthcare - 14 Mar 2024
Dostarlimab given NICE go-ahead in first-line combination treatment for endometrial cancer ...

FDA OKs Dostarlimab Plus Chemo for Endometrial Cancer

Medscape - 31 Jul 2023
FDA OKs Dostarlimab Plus Chemo for Endometrial Cancer ...

Behind the RUBY Trial of Dostarlimab and Chemo for Endometrial Cancer

Targeted Oncology - 24 Jan 2024
Behind the RUBY Trial of Dostarlimab and Chemo for Endometrial Cancer ...

Woman's bowel cancer disappears thanks to 'miracle' drug

BBC.com - 06 Oct 2023
Woman's bowel cancer disappears thanks to 'miracle' drug ...

Dostarlimab Improves OS in Advanced, Recurrent Endometrial Cancer

Cancer Therapy Advisor - 16 Mar 2024
Dostarlimab Improves OS in Advanced, Recurrent Endometrial Cancer ...

FDA Grants Priority Review for Expanded Indication of GSK's Jemperli

BioPharm International - 24 Apr 2024
FDA Grants Priority Review for Expanded Indication of GSK's Jemperli ...

Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial Cancer

Cancer Network - 20 Mar 2024
Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial Cancer ...

Overall Survival in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus ...

OncLive - 29 Mar 2024
Overall Survival in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus ... ...

Dostarlimab/Niraparib Improves PFS Outcomes in Advanced Endometrial Cancer

Cancer Network - 20 Dec 2023
Dostarlimab/Niraparib Improves PFS Outcomes in Advanced Endometrial Cancer ...

CHMP Recommends Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer

OncLive - 16 Oct 2023
CHMP Recommends Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer ...

Dostarlimab Plus Chemo Followed by Dostarlimab/Niraparib Improves PFS in Endometrial Cancer

OncLive - 20 Dec 2023
Dostarlimab Plus Chemo Followed by Dostarlimab/Niraparib Improves PFS in Endometrial Cancer ...

Dostarlimab/Chemo Earns Positive CHMP Opinion in Advanced Endometrial Cancer

Cancer Network - 26 Oct 2023
Dostarlimab/Chemo Earns Positive CHMP Opinion in Advanced Endometrial Cancer ...

Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical Efficacy in Advanced NSCLC

OncLive - 20 Oct 2023
Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical Efficacy in Advanced NSCLC ...

FDA Approves Dostarlimab Plus Chemo for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

OncLive - 31 Jul 2023
FDA Approves Dostarlimab Plus Chemo for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer ...

Dostarlimab